Carbonic Anhydrase Inhibitors Targeting Cancer: Therapeutic, Immunologic, and Diagnostic Tools Targeting Isoforms IX and XII

Drug Design of Zinc-Enzyme Inhibitors: Functional, Structural, and Disease Applications

Volumn , Issue , 2009, Pages 193-222

  Pastorekova, Silvia ^a   Barathova, Monika ^a   Kopacek, Juraj ^a   Pastorek, Jaromir ^a  

^a INSTITUTE OF VIROLOGY   (Slovakia)

Author keywords

Carbonic anhydrase inhibitors targeting cancer; Carbonic anhydrases CA IX and XII interesting molecules from research and clinical view points; Tissue distribution of CA IX and CA XII

Indexed keywords

EID: 84889331040     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470508169.ch8     Document Type: Chapter

References (174)

1. Supuran, C. T. Carbonic anhydrases: novel therapeutic applications for inhibitors and activators. Nat. Rev. Drug Discov. 2008, 7, 168-181.
2. Parkkila, S. An overview of the distribution and function of carbonic anhydrase in mammals, In The Carbonic Anhydrases: New Horizons; Chegwidden,W. R.; Carter, N.; Edwards, Y., Eds.; Birkhauser Verlag: Basil, 2000; pp 76-93.
3. Hilvo, M.; Supuran, C. T.; Parkkila, S. Characterization and inhibition of the recently discovered carbonic anhydrase isoforms CA XIII, XIV and XV. Curr. Top. Med. Chem. 2007, 7, 893-899.
4. Pastorekova, S.; Parkkila, S.; Pastorek, J.; Supuran, C. T. Carbonic anhydrases: current state of the art, therapeutic applications and future prospects. J. Enzyme Inhib. Med. Chem. 2004, 19, 199-229.
5. Brahimi-Horn, M. C.; Pouysségur, J. Hypoxia in cancer cell metabolism and pH regulation. Essays Biochem. 2007, 43, 165-178.
6. Pastorekova, S.; Parkkila, S.; Zavada, J. Tumor-associated carbonic anhydrases and their clinical significance. Adv. Clin. Chem. 2006, 42, 167-216.
7. Pastorekova, S.; Zavadova, Z.; Kostal, M.; Babusikova, O.; Zavada, J. A novel quasiviral agent, MaTu, is a two-component system. Virology 1992, 187, 620-626.
8. Zavada, J.; Zavadova, Z.; Pastorekova, S.; Ciampor, F.; Pastorek, J.;Zelnik,V. Expression of MaTu-MN protein in human tumor cultures and in clinical specimens. Int. J. Cancer. 1993, 54, 268-274.
9. Pastorek, J.; Pastorekova, S.; Callebaut, I.; Mornon, J. P.; Zelnik, V.; Opavsky, R.; Zatovicova, M.; Liao, S.; portetelle, D.; Stanbridge, E. J.; Zavada, J.; Burny, A.; Kettmann, R.; et al. Cloning and characterization of MN, a human tumor-associated protein with a domain homologous to carbonic anhydrase and putative helix-loop-helix DNA binding segment. Oncogene 1994, 9, 2877-2888.
10. Opavsky, R.; Pastorekova, S.; Zelnik, V.; Gibadulinova, A.; Stanbridge, E. J.; Zavada, J.; Kettmann, R.; Pastorek, J. Human MN/CA9 gene, a novel member of the carbonic anhydrase family: structure and exon to protein domain relationships. Genomics 1996, 33, 480-487.
11. Hewett-Emmett, D.; Tashian, R. E. Functional diversity, conservation and convergence in the evolution of the alpha, beta and gamma carbonic anhydrase gene families. Mol. Phylogenet. Evol. 1996, 5, 50-77.
12. Oosterwijk, E. Carbonic anhydrase IX: historical and future perspectives. BJU Int. 2008, 101 (Suppl. 4), 2-7.
13. Hilvo, M.; Baranauskiene, L.; Salzano, A. M.; Scaloni, A.; Matulis, D.; Innocenti, A.; Scozzafava, A.;Monti, S.M.;DiFiore, A.;DeSimone, G.;Lindfors, M.;Jänis, J.;Valjakka, J.;Pastorekovä, S.;Pastorek, J.;Kulomaa, M.S.;Nordlund, H.R.;Supuran, C.T.;Parkkila, S. Biochemical characterization of CA IX: one of the most active carbonic anhydrase isozymes. J. Biol. Chem. 2008, 283 27799-27809. Aug 13. [Epub ahead of print].
14. Dorai, T.; Sawczuk, I. S.; Pastorek, J.; Wiernik, P. H.; Dutcher, J. P. Biological significance of overexpression of carbonic anhydrase IX in renal cell carcinoma:EGF-induced phosphorylation of carbonic anhydrase IX leads to activation of PI-3-kinase pathway in renal cell carcinoma. Eur. J. Cancer 2005, 41, 2935-2947.
15. Wingo, T.; Tu, C.; Laipis, P. J.; Silverman, D. N. The catalytic properties of human carbonic anhydrase IX. Biochem. Biophys. Res. Commun. 2001, 288, 666-669.
16. Vullo, D.; Scozzafava, A.; Pastorekova, S.; Pastorek, J.; Supuran, C. T. Carbonic anhydrase inhibitors: inhibition of the tumor-associated isozyme IX with fluorinecontaining sulfonamides. The first subnanomolar CA IX inhibitor discovered. Bioorg. Med. Chem. Lett. 2004, 14, 2351-2356.
17. Winum, J. Y.; Vullo, D.; Casini, A.; Montero, J. L.; Scozzafava, A.; Supuran, C. T. Carbonic anhydrase inhibitors. Inhibition of cytosolic isozymes I and II and transmembrane, tumor-associated isozyme IX with sulfamates including EMATE also acting as steroid sulfatase inhibitors. J. Med. Chem. 2003, 46, 2197-2204.
18. Türeci, O.; Sahin, U.;Vollmar, E.; Siemer, S.;Göttert, E.; Seitz, G.; Parkkila, A.K.; Shah, G. N.; Grubb, J. H.; Pfreundschuh, M.; Sly,W. S. Human carbonic anhydrase XII: cDNA cloning, expression and chromosomal localization of a carbonic anhydrase gene that is overexpressed in some renal cancers. Proc. Natl. Acad. Sci. USA 1998, 95, 7608-7613.
19. Ivanov, S.V.;Kuzmin, I.;Wei, M. H.; Pack, S.; Geil, L.; Johnson, B. E.; Stanbridge, E. J.; Lerman, M. I. Down-regulation of transmembrane carbonic anhydrases in renal cell carcinoma cell lines by wild-type von Hippel-Lindau transgenes. Proc. Natl. Acad. Sci. USA 1998, 95, 12596-12601.
20. Ulmasov,B.;Waheed, A.; Shah, G.N.; Grubb, J.H.; Sly, W. S.; Tu, C.; Silverman,D. N. Purification and kinetic analysis of recombinant CA XII, a membrane carbonic anhydrase overexpressed in certain cancers. Proc. Natl. Acad. Sci. USA 2000, 97, 14212-14217.
21. Pastorekova, S.; Parkkila, S.; Parkkila, A. K.; Opavsky, R.; Zelník, V.; Saarnio, J.; Pastorek, J. Carbonic anhydrase IX, MN/CA IX: analysis of stomach complementary DNA sequence and expression in human and rat alimentary tracts. Gastroenterology 1997, 112, 398-408.
22. Saarnio, J.; Parkkila, S.; Parkkila, A. K.; Waheed, A.; Casey, M. C.; Zhou, X. Y.; Pastorekova, S.; Pastorek, J.; Karttunen, T.; Haukipuro, K.; Kairaluoma, M. I.; Sly,W. S. Immunohistochemistry of carbonic anhydrase isozyme IX (MN/CA IX) in human gut reveals polarized expression in the epithelial cells with the highest proliferative capacity. J. Histochem. Cytochem. 1998, 46, 497-504.
23. Kivela, A.; Parkkila, S.; Saarnio, J.; Karttunen, T. J.; Kivela, J.; Parkkila, A. K.; Pastorekova, S.; Pastorek, J.; Waheed, A.; Sly, W. S.; Rajaniemi, H. Expression of transmembrane carbonic anhydrase isozymes IX and XII in normal human pancreas and pancreatic tumors. Histochem. Cell. Biol. 2000, 114, 197-204.
24. Karhumaa, P.; Kaunisto, K.; Parkkila, S.;Waheed, A.; Pastorekova, S.; Pastorek, J.; Sly, W. S.; Rajaniemi, H. Expression of the transmembrane carbonic anhydrases, CA IX and CA XII, in the human male excurrent ducts. Mol. Hum. Reprod. 2001, 7, 611-616.
25. Ivanov, S.; Liao, S. Y.; Ivanova, A.; Danilkovich-Miagkova, A.; Tarasova, N.;Weirich, G.; Merrill, M. J.; Proescholdt, M. A.; Oldfield, E. H.; Lee, J.; Zavada, J.;Waheed, A.; Sly, W.; Lerman, M. I.; Stanbridge, E. J. Expression of hypoxia-inducible cell-surface transmembrane carbonic anhydrases in human cancer. Am. J. Pathol. 2001, 158, 905-919.
26. Liao, S. Y.; Brewer, C.; Zavada, J.; Pastorek, J.; Pastorekova, S.; Manetta, A.; Berman, M. L.; DiSaia, P. J.; Stanbridge, E. J. Identification of the MN antigen as a diagnostic biomarker of cervical intraepithelial squamous and glandular neoplasia and cervical carcinomas. Am. J. Pathol. 1994, 145, 598-609.
27. Turner, J. R.; Odze, R. D.; Crum, C. P.; Resnick, M. B. MNantigen expression in normal, preneoplastic and neoplastic esophagus: a clinicopathological study of a new cancerassociated biomarker. Hum. Pathol. 1997, 28, 740-744.
28. Liao, S.Y.; Aurelio, O. N.; Jan, K.; Zavada, J.; Stanbridge, E. J. Identification of the MN/CA9 protein as a reliable diagnostic biomarker of clear cell carcinoma of the kidney. Cancer Res. 1997, 57, 2827-2831.
29. McKiernan, J. M.; Buttyan, R.; Bander, N. H.; Stifelman, M. D.; Katz, A. E.; Olsson, C. A.; Sawczuk, I. S. Expression of the tumour-associated gene MN: a potential biomarker for human renal cell carcinoma. Cancer Res. 1997, 57, 2362-2365.
30. Vermylen, P.; Roufosse, C.; Burny, A.; Verhest, A.; Bossehaerts, T.; Pastorekova, S.; Ninane, V.; Sculier, J. P. Carbonic anhydrase IX antigen differentiates between preneoplastic and malignant lesions in non-small cell lung carcinomas. Eur. Respir. J. 1999, 14, 806-811.
31. Bartosova, M.; Parkkila, S.; Pohlodek, K.; Karttunen, T. J.; Galbavy, S.; Mucha, V.; Harris, A. L.; Pastorek, J.; Pastorekova, S. Expression of carbonic anhydrase IX in breast is associated with malignant tissues and related to overexpression of c-erbB2. J. Pathol. 2002, 197, 1-8.
32. Haapasalo, J.; Nordfors, K.; Hilvo, M.; Rantala, I.; Soini,Y.; Parkkila, A. K.; Pastorekova, S.; Pastorek, J.; Parkkila, S.; Haapasalo, H. K. Expression of carbonic anhydrase IX in astrocytic tumors predicts poor prognosis. Clin. Cancer Res. 2006, 12, 473-477.
33. Leppilampi, M.; Saarnio, J.; Karttunen, T. J.; Kivelä, J.; Pastorekovä, S.; Pastorek, J.; Waheed, A.; Sly, W. S.; Parkkila, S. Carbonic anhydrase isozymes IX and XII in gastric tumors. World J. Gastroenterol. 2003, 9, 1398-1403.
34. Saarnio, J.; Parkkila, S.; Parkkila, A. K.; Pastorekovä, S.; Haukipuro, K.; Pastorek, J.; Juvonen, T.; Karttunen, T. J. Transmembrane carbonic anhydrase, MN/CA IX, is a potential biomarker for biliary tumours. J. Hepatol. 2001, 35, 643-649.
35. Saarnio, J.; Parkkila, S.; Parkkila, A. K.; Haukipuro, K.; Pastorekova, S.; Pastorek, J.; Kairaluoma, M. I.; Karttunen, T. J. Immunohistochemical study of colorectal tumors for expression of a novel transmembrane carbonic anhydrase, MN/CA IX, with potential value as a marker of cell proliferation. Am. J. Pathol. 1998, 153, 279-285.
36. Liao, S. Y.; Stanbridge, E. J. Expression of the MN antigen in cervical papanicolaou smears is an early diagnostic biomarker of cervical dysplasia. Cancer Epidemiol. Biomarkers Prev. 1996, 5, 549-557.
37. Liao, S. Y.; Stanbridge, E. J. Expression of MN/CA9 protein in Papanicolaou smears containing atypical glandular cells of undetermined significance is a diagnostic biomarker of cervical dysplasia and neoplasia. Cancer 2000, 88, 1108-1121.
38. Watson, P. H.; Chia, S. K.;Wykoff, C. C.; Han, C.; Leek, R. D.; Sly, W. S.; Gatter, K. C.; Ratcliffe, P. J.; Harris, A. L. Carbonic anhydrase XII is a marker of good in invasive breast carcinoma. Br. J. Cancer 2003, 88, 1065-1070.
39. Kivela, A. J.; Parkkila, S.; Saarnio, J.; Karttunen, T. J.; Kivela, J.; Parkkila, A. K.; Bartosova, M.; Mucha, V.; Novak, M.; Waheed, A.; Sly, W. S.; Rajaniemi, H.; Pastorekova, S.; Pastorek, J. Expression of von Hippel-Lindau tumor suppressor and tumorassociated carbonic anhydrases IX and XII in normal and neoplastic colorectal mucosa. World J. Gastroenterol. 2005, 11, 2616-2625.
40. Kim, J.Y.;Shin, H. J.;Kim, T.H.;Cho, K.H.; Shin, K.H.; Kim, B. K.;Roh, J.W.;Lee, S.; Park, S. Y.; Hwang, Y. J.; Han, I. O. Tumor-associated carbonic anhydrases are linked to metastases in primary cervical cancer. J. Cancer Res. Clin. Oncol. 2006, 132, 302-308.
41. Hynninen, P.; Vaskivuo, L.; Saarnio, J.; Haapasalo, H.; Kivelä, J.; Pastorekovä, S.; Pastorek, J.; Waheed, A.; Sly, W. S.; Puistola, U.; Parkkila, S. Expression of transmembrane carbonic anhydrases IX and XII in ovarian tumours. Histopathology 2006, 49, 594-602.
42. Haapasalo, J.; Hilvo, M.; Nordfors, K.; Haapasalo, H.; Parkkila, S.; Hyrskyluoto, A.; Rantala, I.; Waheed, A.; Sly, W. S.; Pastorekova, S.; Pastorek, J.; Parkkila, A. K. Identification of an alternatively spliced isoform of carbonic anhydrase XII in diffusely infiltrating astrocytic gliomas. Neuro Oncol. 2008, 10, 131-138.
43. Hynninen, P.; Hamalainen, J. M.; Pastorekova, S.; Pastorek, J.;Waheed, A.; Sly, W. S.; Tomas, E.; Kirkinen, P.; Parkkila, S. Transmembrane carbonic anhydrase isozymes IX and XII in the female mouse reproductive tract. Reprod. Biol. Endocrinol. 2004, 2, 73.
44. Karhumaa, P.; Parkkila, S.; Tureci, O.;Waheed, A.; Grubb, J. H.; Shah, G.; Parkkila, S.; Kaunisto, K.; Tapanainen, J.; Sly, W. S.; Rajaniemi, H. Identification of carbonic anhydrase XII as the membrane isozyme expressed in the normal human endometrial epithelium. Mol. Hum. Reprod. 2000, 6, 68-74.
45. Parkkila, S.; Parkkila, A. K.; Saarnio, J.; Kivela, J.; Karttunen, T. J.; Kaunisto, K.; Waheed, A.; Sly, W. S.; Tureci, O.; Virtanen, I.; Rajaniemi, H. Expression of the membrane-associated carbonic anhydrase isozyme XII in the human kidney and renal tumors. J. Histochem. Cytochem. 2000, 48, 1601-1608.
46. Liao, S.Y.; Ivanov, S.; Ivanova, A.; Ghosh, S.; Cote, M. A.;Keefe, K.; Coca-Prados, M.; Stanbridge, E. J.; Lerman, M. I. Expression of cell surface transmembrane carbonic anhydrase genes CA9 and CA12 in the human eye: overexpression of CA12 (CAXII) in glaucoma. J. Med. Genet. 2003, 40, 257-261.
47. Gottsch, J. D.; Seitzman, G. D.; Margulies, E. H.; Bowers, A. L.; Michels, A. J.; Saha, S.; Jun, A. S.; Stark, W. J.; Liu, S. H. Gene expression in donor corneal endothelium. Arch. Ophthalmol. 2003, 121, 252-258.
48. Kallio, H.; Pastorekova, S.; Pastorek, J.; Waheed, A.; Sly, W. S.; Mannisto, S.; Heikinheimo, M.; Parkkila, S. Expression of carbonic anhydrases IX and XII during mouse embryonic development. BMC Dev. Biol. 2006, 6, 22.
49. Kaluz, S.; Kaluzova, M.; Opavsky, R.; Pastorekova, S.; Gibadulinova, A.; Dequiedt, F.; Kettmann, R.; Pastorek, J. Transcriptional regulation of the MN/CA9 gene coding for the tumor-associated carbonic anhydrase IX. Identification and characterization of a proximal silencer element. J. Biol. Chem. 1999, 274, 32588-32595.
50. Kaluzova, M.; Pastorekova, S.; Svastova, E.; Pastorek, J.; Stanbridge, E. J.; Kaluz, S. Characterization of the MN/CA9 proximal region: a role for SP and AP1 factors. Biochem. J. 2001, 359, 669-677.
51. Wykoff, C.; Beasley, N.;Watson, P.;Turner,K. J.; Pastorek, J.; Sibtain, A.;Wilson, G. D.; Turley, H.; Talks, K. L.; Maxwell, P. H.; Pugh, C. W.; Ratcliffe, P. J.; Harris, A. L. Hypoxia-inducible regulation of tumor-associated carbonic anhydrases. Cypoxia-inducible regulation of tumor-associated carbonic anhydrases. Cancer Res. 2000, 60, 7075-7083.
52. Kaelin,W. G., Jr.; Ratcliffe, P. J. Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway. Mol. Cell. 2008, 30, 393-402.
53. Coleman, M. L.; Ratcliffe, P. J. Oxygen sensing and hypoxia-induced responses. Essays Biochem. 2007, 43, 1-15.
54. Ruas, J. L.; Poellinger, L. Hypoxia-dependent activation of HIF into a transcriptional regulator. Semin. Cell Dev. Biol. 2005, 16, 514-522.
55. Kaluz, S.; Kaluzova, M.; Chrastina, A.; Olive, P. L.; Pastorekova, S.; Pastorek, J.; Lerman, M. I.; Stanbridge, E. J. Lowered oxygen tension induces expression of the hypoxia marker MN/carbonic anhydrase IX in the absence of hypoxia-inducible factor 1a stabilization: a role for phosphatidylinositol 30-kinase. Cancer Res. 2002, 62, 4469-4477.
56. Kopacek, J.; Barathova, M.; Dequiedt, F.; Sepelakova, J.; Kettmann, R.; Pastorek, J.; Pastorekova, S. MAPK pathway contributes to density-and hypoxia-induced expression of the tumor-associated carbonic anhydrase IX. Biochim. Biophys. Acta 2005, 1729, 41-49.
57. Mandriota, S. J.; Turner, K. J.; Davies, D. R.; Murray, P. G.; Morgan, N.V.; Sowter, H. M.; Wykoff, C. C.; Maher, E. R.; Harris, A. L.; Ratcliffe, P. J.; Maxwell, P. H. HIF activation identifies early lesions in VHL kidneys: evidence for site-specific tumor suppressor function in the nephron. Cancer Cell 2002, 1, 459-468.
58. Cho, M.; Grabmaier, K.; Kitahori, Y.; Hiasa, Y.; Nakagawa, Y.; Uemura, H.; Hirao, Y.; Ohnishi, T.;Yoshikawa, K.; Ooesterwijk, E. Activation of the MN/CA9 gene is associated with hypomethylation in human renal cell carcinoma cell lines. Mol. Carcinog. 2000, 27, 184-189.
59. Cho, M.; Uemura, H.; Kim, S. C.; Kawada, Y.; Yoshida, K.; Hirao, Y.; Konishi, N.; Saga, S.; Oshikawa, K. Hypomethylation of the MN/CA9 promoter and upregulated MN/CA9 expression in human renal cell carcinoma. Br. J. Cancer 2001, 85, 563-567.
60. Jakubickova, L.; Biesova, Z.; Pastorekova, S.; Kettmann, R.; Pastorek, J. Methylation of the CA9 promoter can modulate expression of the tumor-associated carbonic anhydrase IX in dense carcinoma cell lines. Int. J. Oncol. 2005, 26, 1121-1127.
61. Barnett, D. H.; Sheng, S.; Charn, T. H.; Waheed, A.; Sly, W. S.; Lin, C. Y.; Liu, E. T.; Katzenellenbogen, B. S. Estrogen receptor regulation of carbonic anhydrase XII through a distal enhancer in breast cancer. Cancer Res. 2008, 68, 3505-3515.
62. Barathova, M.;Takacova, M.;Holotnakova,T.;Gibadulinova, A.;Ohradanova, A.; Zatovicova, M.;Hulikova, A.;Kopacek, J.; Parkkila, S.;Supuran,C.T.;Pastorekova, S.; Pastorek, J. Alternative splicing variant of the hypoxia marker carbonic anhydrase IX expressed independently of hypoxia and tumour phenotype. Br. J. Cancer 2008, 98, 129-136.
63. Rafajova, M.; Zatovicova, M.; Kettmann, R.; Pastorek, J.; Pastorekova, S. Induction by hypoxia combined with low glucose or low bicarbonate and high posttranslational stability upon reoxygenation contribute to carbonic anhydrase IX expression in cancer cells. Int. J. Oncol. 2004, 24, 995-1004.
64. Zatovicova, M.; Sedlakova, O.; Svastova, E.; Ohradanova, A.; Ciampor, F.; Arribas, J.; Pastorek, J.; Pastorekova, S. Ectodomain shedding of the hypoxia-induced carbonic anhydrase IX is a metalloprotease-dependent process regulated by TACE/ADAM17. Br. J. Cancer 2005, 93, 1267-1276.
65. Zavada, J.; Zavadova, Z.; Zatovicova, M.; Hyrsl, L.; Kawaciuk, I. Soluble form of carbonic anhydrase IX (CA IX) in the serum and urine of renal carcinoma patients. Br. J. Cancer 2003, 89, 1067-1071.
66. Li, G.; Feng, G.; Gentil-Perret, A.; Genin, C.; Tostain, J. Serum carbonic anhydrase 9 level is associated with postoperative recurrence of conventional renal cell cancer. J. Urol. 2008, 180, 510-513.
67. Vaupel, P.; Mayer, A. Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metastasis Rev. 2007, 26, 225-239.
68. Moon,E. J.; Brizel,D. M.;Chi, J.T.;Dewhirst,M.W. The potential role of intrinsic hypoxia markers as prognostic variables in cancer. Antioxid. Redox Signal. 2007, 9, 1237-1294.
69. Beasley, N. J.;Wykoff, C. C.;Watson, P. H.; Leek, R.; Turley, H.; Gatter, K.; Pastorek, J.; Cox, G. J.; Ratcliffe, P.; Harris, A. L. Carbonic anhydrase IX, an endogenous hypoxia marker, expression in head and neck squamous cell carcinoma and its relationship to hypoxia, necrosis and microvessel density. Cancer Res. 2001, 61, 5262-5267.
70. Turner,K. J.; Crew, J. P.;Wykoff, C. C.;Watson, P. H.; Poulsom, R.; Pastorek, J.; Ratcliffe, P. J.; Cranston, D.; Harris, A. L. The hypoxia-inducible genes VEGF and CA9 are differentially regulated in superficial vs invasive bladder cancer. Br. J. Cancer 2002, 86, 1276-1282.
71. Swinson, D. E.; Jones, J. L.; Richardson, D.;Wykoff, C.; Turley, H.; Pastorek, J.; Taub, N.; Harris, A. L.; O'Byrne, K. J. Carbonic anhydrase IX expression, a novel surrogate marker of tumor hypoxia, is associated with a poor prognosis in non-small-cell lung cancer. J. Clin. Oncol. 2003, 21, 473-482.
72. Olive, P. L.; Aquino-Parsons, C.; MacPhail, S. H.; Laio, S.; Raleigh, J. A.; Lerman, M. I.; Stanbridge, E. J. Carbonic anhydrase 9 as an endogenous marker for hypoxic cells in cervical cancer. Cancer Res. 2001, 61, 8924-8929.
73. Shin, K. H.; Diaz-Gonzalez, J. A.; Russell, J.; Chen, Q.; Burgman, P.; Li, X. F.; Ling, C. C. Detecting changes in tumor hypoxia with carbonic anhydrase IX and pimonidazole. Cancer Biol. Ther. 2007, 6, 70-75.
74. Wykoff, C. C.; Beasley, N.;Watson, P. H.; Campo, L.; Chia, S. K.; English, R.; Pastorek, J.; Sly, W. S.; Ratcliffe, P.; Harris, A. L. Expression of the hypoxia-inducible and tumorassociated carbonic anhydrases in ductal carcinoma in situ of the breast. Am. J. Pathol. 2001, 158, 1011-1019.
75. Chia, S. K.;Wykoff,C. C.;Watson, P. H.; Han, C.; Leek, R. D.; Pastorek, J.; Gatter, K. C.; Ratcliffe, P.; Harris, A. L. Prognostic significance of a novel hypoxia-regulated marker, carbonic anhydrase IX, in invasive breast carcinoma. J. Clin. Oncol. 2001, 19, 3660-3668.
76. Giatromanolaki, A.;Koukourakis, M. I.; Sivridis, E.; Pastorek, J.;Wykoff, C. C.; Gatter, K. C.; Harris, A. L. Expression of hypoxia-inducible carbonic anhydrase-9 relates to angiogenic pathways and independently to poor outcome in non-small cell lung cancer. Cancer Res. 2001, 61, 7992-7998.
77. Generali, D.; Fox, S. B.; Berruti, A.; Brizzi, M. P.; Campo, L.; Bonardi, S.;Wigfield, S. M.; Bruzzi, P.; Bersiga, A.; Allevi, G.; Milani, M.; Aguggini, S.; Dogliotti, L.; Bottini, A.; Harris, A. L. Role of carbonic anhydrase IX expression in prediction of the efficacy and outcome of primary epirubicin/tamoxifen therapy for breast cancer. Endocr. Relat. Cancer 2006, 13, 921-930.
78. Brennan, D. J.; Jirstrom, K.; Kronblad, A.; Millikan, R. C.; Landberg, G.; Duffy, M. J.; Rydén, L.; Gallagher, W. M.; O'Brien, S. L. CA IX is an independent prognostic marker in premenopausal breast cancer patients with one to three positive lymph nodes and a putative marker of radiation resistance. Clin. Cancer Res. 2006, 12, 6421-6431.
79. Hussain, S. A.; Ganesan, R.; Reynolds, G.; Gross, L.; Stevens, A.; Pastorek, J.; Murray, P. G.; Perunovic, B.; Anwar, M. S.; Billingham, L.; James, N. D.; Spooner, D.; Poole, C. J.; Rea, D. W.; Palmer, D. H. Hypoxia-regulated carbonic anhydrase IX expression is associated with poor survival in patients with invasive breast cancer. Br. J. Cancer 2007, 96, 104-109.
80. Trastour, C.; Benizri, E.; Ettore, F.; Ramaioli, A.; Chamorey, E.; Pouysségur, J.; Berra, E. HIF-1alpha and CAIX staining in invasive breast carcinomas: prognosis and treatment outcome. Int. J. Cancer 2007, 120, 1451-1458.
81. Kon-no,H.; Ishii, G.; Nagai, K.;Yoshida, J.; Nishimura, M.; Nara, M.; Fujii, T.;Murata, Y.;Miyamoto, H.; Ochiai, A. Carbonic anhydrase IX expression is associated with tumor progression andapoor prognosis of lungadenocarcinoma. Lung Cancer 2006,54,409-418.
82. Le, Q. T.; Kong, C.; Lavori, P.W.; O'Byrne, K.; Erler, J. T.; Huang, X.; Chen, Y.; Cao, H.; Tibshirani, R.; Denko, N.; Giaccia, A. J.; Koong, A. C. Expression and prognostic significance of a panel of tissue hypoxia markers in head-and-neck squamous cell carcinomas. Int. J. Radiat. Oncol. Biol. Phys. 2007, 69, 167-175.
83. Korkolopoulou, P.; Perdiki, M.; Thymara, I.; Boviatsis, E.; Agrogiannis, G.; Kotsiakis, X.; Angelidakis, D.; Rologis, D.; Diamantopoulou, K.; Thomas-Tsagli, E.; Kaklamanis, L.; Gatter, K.; Patsouris, E. Expression of hypoxia-related tissue factors in astrocytic gliomas. A multivariate survival study with emphasis upon carbonic anhydrase IX. Hum. Pathol. 2007, 38, 629-638.
84. Chen, J.; Röcken, C.; Hoffmann, J.; Krüger, S.; Lendeckel, U.; Rocco, A.; Pastorekova, S.; Malfertheiner, P.; Ebert, M. P. Expression of carbonic anhydrase 9 at the invasion front of gastric cancers. Gut 2005, 54, 920-927.
85. Driessen,A.; Landuyt, W.; Pastorekova, S.;Moons, J.;Goethals, L.;Haustermans, K.; Nafteux, P.; Penninckx, F.; Geboes, K.; Lerut, T.; Ectors, N. Expression of carbonic anhydrase IX (CA IX), a hypoxia-related protein, rather than vascular-endothelial growth factor (VEGF), a pro-angiogenic factor, correlates with an extremely poor prognosis in esophageal and gastric adenocarcinomas. Ann. Surg. 2006, 243, 334-340.
86. Ord, J. J.; Streeter, E. H.; Roberts, I. S.; Cranston, D.; Harris, A. L. Comparison of hypoxia transcriptome in vitro with in vivo gene expression in human bladder cancer. Br. J. Cancer 2005, 93, 346-354.
87. Winter, S. C.; Buffa, F. M.; Silva, P.; Miller, C.; Valentine, H. R.; Turley, H.; Shah, K. A.; Cox, G. J.; corbridge, R. J.; Homer, J. J.; Musgrove, B.; Slevin, N.; Sloan, P.; Price, P.;West, C. M.; Harris, A. L. Relation of a hypoxia metagene derived from head and neck cancer to prognosis of multiple cancers. Cancer Res. 2007, 67, 3441-3449.
88. Kaelin W. G., Jr. The von Hippel-Lindau tumor suppressor protein and clear cell renal carcinoma. Clin. Cancer Res. 2007, 13, 680s-684s.
89. Wiesener,M. S.; Munchenhagen, P. M.; Berger, I.; Morgan, N.V.; Roigas, J.; Schwiertz, A.; Jurgensen, J. S.; Gruber, G.; Maxwell, P. H.; Loning, S. A.; Frei, U.; Maher, E. R.; Grone, H. J.; Eckhardt, K. U. Constitutive activation of hypoxia-inducible genes related to overexpression of hypoxia-inducible factor-1a in clear cell renal carcinomas. Cancer Res. 2001, 61, 5215-5222.
90. Raval, R. R.; Lau, K.W.; Tran, M. G.; Sowter, H. M.; Mandriota, S. J.; Li, J. L.; Pugh, C. W.; Maxwell, P. H.; Harris, A. L.; Ratcliffe, P. J. Contrasting properties of hypoxiainducible factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-associated renal cell carcinoma. Mol. Cell Biol. 2005, 25, 5675-5686.
91. Bui, M. H.; Seligson, D.; Han, K. R.; Pantuck, A. J.; Dorey, F. J.; Huang, Y.; Horvath, S.; Leibovich, B. C.; Chopra, S.; Liao, S. Y.; Stanbridge, E. J.; Lerman, M. I.; Palotie, A.; Figlin, R. A.; Belldegrun, A. S. Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy. Clin. Cancer Res. 2003, 9, 802-811.
92. Bui, M. H.; Visapaa, H.; Seligson, D.; Kim, H.; Han, K. R.; Huang, Y.; Horvath, S.; Stanbridge, E. J.; Palotie, A.; Figlin, R. A.; Belldegrun, A. S. Prognostic value of carbonic anhydrase IX and Ki67 as predictors of survival for renal clear cell carcinoma. J. Urol. 2004, 171, 2461-2466.
93. Sandlund, J.; Oosterwijk, E.; Grankvist, K.; Oosterwijk-Wakka, J.; Ljungberg, B.; Rasmuson, T. Prognostic impact of carbonic anhydrase IX expression in human renal cell carcinoma. BJU Int. 2007, 100, 556-560.
94. Patard, J. J.; Fergelot, P.; Karakiewicz, P. I.; Klatte, T.; Trinh, Q. D.; Rioux-Leclercq, N.; Said, J.W.; Belldegrun, A. S.; Pantuck, A. J. Low CAIX expression and absence of VHL gene mutation are associated with tumor aggressiveness and poor survival of clear cell renal cell carcinoma. Int. J. Cancer 2008, 123, 395-400.
95. Pantuck, A. J.; Klatte, T.; Seligson, D.; Atkins, M.; Belldegrun, A. Carbonic anhydrase IX as a predictive biomarker for clear cell renal cell carcinoma. J. Clin. Oncol. 2008, 26, 3105-3107.
96. Brouwers, A. H.; Frielink, C.; Oosterwijk, E.; Oyen, W. J.; Corstens, F. H.; Boerman, O. C. Interferons can upregulate the expression of the tumor associated antigen G250-MN/CA IX, a potential target for (radio)immunotherapy of renal cell carcinoma. Cancer Biother. Radiopharm. 2003, 18, 539-547.
97. Atkins,M.; Regan, M.;McDermott, D.;Mier, J.; Stanbridge, E.; Youmans, A.; Febbo, P.; Upton, M.; Lechpammer, M.; Signoretti, S. Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer. Clin. Cancer Res. 2005, 11, 3714-3721.
98. Shuch, B.; Li, Z.; Belldegrun, A. S. Carbonic anhydrase IX and renal cell carcinoma:prognosis, response to systemic therapy, and future vaccine strategies. BJU Int. 2008, 101 (Suppl. 4), 25-30.
99. Pantuck, A. J.; Zeng, G.; Belldegrun, A. S.; Figlin, R. A. Pathobiology, prognosis, and targeted therapy for renal cell carcinoma: exploiting the hypoxia-induced pathway. Clin. Cancer Res. 2003, 9, 4641-4652.
100. Tunuguntla, H. S.; Jorda, M. Diagnostic and prognostic molecular markers in renal cell carcinoma. J. Urol. 2008, 179, 2096-2102.
101. Swinson, D. E.; Jones, J. L.; Cox, G.; Richardson, D.; Harris, A. L.; O'Byrne, K. J. Hypoxia-inducible factor-1 alpha in non small cell lung cancer: relation to growth factor, protease and apoptosis pathways. Int. J. Cancer 2004, 111, 43-50.
102. Le,Q. T.; Chen, E.; Salim, A.; Cao, H.;Kong, C. S.;Whyte,R.; Donington, J.;Cannon, W.;Wakelee, H.; Tibshirani, R.; Mitchell, J.D.; Richardson, D.; Obyrne, K. J.;Koong, A. C.;Giaccia,A. J. An evaluation of tumor oxygenation and gene expression in patients with early stage non-small cell lung cancers. Clin. Cancer Res. 2006, 12, 1507-1514.
103. Vleugel, M. M.; Shvarts, D.; van der Wall, E.; van Diest, P. J. p300 and p53 levels determine activation of HIF-1 downstream targets in invasive breast cancer. Hum. Pathol. 2006, 37, 1085-1092.
104. Storci, G.; Sansone, P.; Trere, D.; Tavolari, S.; Taffurelli, M.; Ceccarelli, C.; Guarnieri, T.; Paterini, M.; Pariali, M.; Montanaro, L.; Santini, D.; Chieco, P.; Bonafe, M. The basal-like breast carcinoma phenotype is regulated by SLUG gene expression. J. Pathol. 2008, 214, 25-37.
105. Jarvela, S.; Parkkila, S.; Bragge, H.; Kahkonen, M.; Parkkila, A. K.; Soini, Y.; Pastorekova, S.; Pastorek, J.; Haapasalo, H. Carbonic anhydrase IX in oligodendroglial brain tumors. BMC Cancer 2008, 8, 1.
106. Sansone, P.; Storci, G.; Tavolari, S.; Guarnieri, T.; Giovannini, C.; Taffurelli, M.; Ceccarelli, C.; Santini, D.; Paterini, P.; Marcu, K. B.; Chieco, P.; Bonafe, M. IL-6 triggers malignant features in mammospheres from human ductal breast carcinoma and normal mammary gland. J. Clin. Invest. 2007, 117, 3988-4002.
107. Kivela, A.; Parkkila, S.; Saarnio, J.; Karttunen, T. J.; Kivela, J.; Parkkila, A. K.;Waheed, A.; Sly, W. S.; Grubb, J. H.; Shah, G.; Tureci, O.; Rajaniemi, H. Expression of a novel transmembrane carbonic anhydrase isozyme XII in normal human gut and colorectal tumors. Am. J. Pathol. 2000, 156, 577-584.
108. Svastova, E.; Hulikova, A.; Rafajova, M.; Zat'ovicova, M.; Gibadulinova, A.; Casini, A.; Scozzafava, A.; Supuran, C. T.; Pastorek, J.; Pastorekova, S. Hypoxia activates the capacity of tumor-associated carbonic anhydrase IX to acidify extracellular pH. FEBS Lett. 2004, 577, 439-495.
109. Robertson, N.; Potter, C.; Harris, A. L. Role of carbonic anhydrase IX in human tumor cell growth, survival, and invasion. Cancer Res. 2004, 64, 6160-6165.
110. Swietach, P.; Wigfield, S.; Cobden, P.; Supuran, C. T.; Harris, A. L.; Vaughan-Jones, R. D. Tumor-associated carbonic anhydrase 9 spatially coordinates intracellular pH in three-dimensional multicellular growths. J. Biol. Chem. 2008, 283, 20473-20483.
111. Chiche, J.; Ilc, K.; Laferrière, J.; Trottier, E.; Dayan, F.; Mazure, N. M.; Brahimi-Horn, M. C.; Pouysségur, J. Hypoxia-inducible carbonic anhydrase IX and XII promote tumor cell growth by counteracting acidosis through the regulation of the intracellular pH. Cypoxia-inducible carbonic anhydrase IX and XII promote tumor cell growth by counteracting acidosis through the regulation of the intracellular pH. Cancer Res. 2009, 69, 358-368.
112. Stubbs, M.;McSheehy, P.M. J.;Griffiths, J. R.;Bashford, C. L. Causes andconsequences of tumor acidity and implications for treatment. Mol. Med. Today 2000, 6, 15-19.
113. Helmlinger, G.; Sckell, A.; Dellian, M.; Forbes, N. S.; Jain, R. K. Acid production in glycolysis-impaired tumors provides new insights into tumor metabolism. Clin. Cancer Res. 2002, 8, 1284-1291.
114. Fukumura, D.; Jain, R. K. Tumor microenvironment abnormalities: causes, consequences, and strategies to normalize. J. Cell. Biochem. 2007, 101, 937-949.
115. Karumanchi, S. A.; Jiang, L.; Knebelmann, B.; Stuart-Tilley, A. K.; Alper, S. L.; Sukhatme, V. P. VHL tumor suppressor regulates Cl-/HCO3-exchange and Na{thorn}/H{thorn} exchange activities in renal carcinoma cells. Physiol. Genomics 2001, 5, 119-128.
116. Shimoda, L. A.; Fallon, M.; Pisarcik, S.; Wang, J.; Semenza, G. L. HIF-1 regulates hypoxic induction of NHE1 expression and alkalinization of intracellular pH in pulmonary arterial myocytes. Am. J. Physiol. Lung Cell. Mol. Physiol. 2006, 291, L941-L949.
117. Ullah, M. S.; Davies, A. J.; Halestrap, A. P. The plasma membrane lactate transporter MCT4, but not MCT1, is up-regulated by hypoxia through a HIF-1alpha-dependent mechanism. J. Biol. Chem. 2006, 281, 9030-9037.
118. Casey, J. R. Why bicarbonate? Biochem. Cell Biol. 2006, 84, 930-939.
119. Innocenti, A.;Vullo, D.; Scozzafava, A.; Casey, J. R.; Supuran, C. T. Carbonic anhydrase inhibitors. Interaction of isozymes I, II, IV, V, and IX with carboxylates. Bioorg. Med. Chem. Lett. 2005, 15, 573-578.
120. Morgan, P. E.; Pastorekovä, S.; Stuart-Tilley, A. K.; Alper, S. L.; Casey, J. R. Interactions of transmembrane carbonic anhydrase, CAIX, with bicarbonate transporters. Am. J. Physiol. Cell Physiol. 2007, 293, C738-C748.
121. Fukumura, D.; Jain, R. K. Tumor microvasculature and microenvironment: targets for anti-angiogenesis and normalization. Microvasc. Res. 2007, 74, 72-84.
122. Raghunand, N.; Gatenby, R. A.; Gillies, R. J. Microenvironmental and cellular consequences of altered blood flow in tumours. Br. J. Radiol. 2003, 76, S11-22.
123. Zävada, J.; Zävadovä, Z.; Pastorek, J.; Biesovä, Z.; Jezek, J.; Velek, J. Human tumourassociated cell adhesion protein MN/CA IX: identification of M75 epitope and of the region mediating cell adhesion. Br. J. Cancer 2000, 82, 1808-1813.
124. Zavadova, Z.; Zavada, J. Carbonic anhydrase IX (CA IX) mediates tumor cell interactions with microenvironment. Oncol. Rep. 2005, 13, 977-982.
125. Svastovä, E.; Zilka, N.; Zat'ovicovä, M.; Gibadulinovä, A.; Ciampor, F.; Pastorek, J.; Pastorekovä, S. Carbonic anhydrase IX reduces E-cadherin-mediated adhesion ofMDCK cells via interaction with beta-catenin. Exp. Cell Res. 2003, 290, 332-345.
126. Parkkila, S.; Rajaniemi, H.; Parkkila, A. K.; Kivela, J.; Waheed, A.; Pastorekova, S.; Pastorek, J.; Sly,W. S. Carbonic anhydrase inhibitor suppresses invasion of renal cancer cells in vitro. Proc. Natl. Acad. Sci. USA 2000, 97, 2220-2224.
127. Zatovicova, M.; Tarabkova, K.; Svastova, E.; Gibadulinova, A.; Mucha, V.; Jakubickova, L.; Biesova, Z.; Rafajova, M.; Ortova Gut, M.; Parkkila, S.; Parkkila, A. K.; Waheed, A.; Sly, W. S.; Horak, I.; Pastorek, J.; Pastorekova, S. Monoclonal antibodies generated in carbonic anhydrase IX-deficient mice recognize different domains of tumour-associated hypoxia-induced carbonic anhydrase IX. J. Immunol. Methods 2003, 282, 117-134.
128. Carney, W. P. Circulating oncoproteins HER2/neu, EGFR and CAIX (MN) as novel cancer biomarkers. Expert Rev. Mol. Diagn. 2007, 7, 309-319.
129. Lam, J. S.; Pantuck, A. J.; Belldegrun, A. S.; Figlin, R. A. G250: a carbonic anhydrase IX monoclonal antibody. Curr. Oncol. Rep. 2005, 7, 109-115.
130. Divgi, C. The use of positron-emission tomography in the diagnosis of tumour phenotype. BJU Int. 2008, 101, 36-38.
131. Supalova, L.; Hulikova, A.; Barathova, M.; Gibadulinova, A.; Parkkila, S.; Supuran, C. T.; Pastorek, J.; Pastorekova, S.; Zatovicova, M. Characterization of G250 monoclonal antibody binding to human cancer-associated carbonic anhydrase IX. In Abstract booklet from International CA IX Symposium: Functional and Clinical Aspects, November 14, 2007, Abstract No. 3.
132. Pastorekova, S.; Zavada, J. Carbonic anhydrase IX (CA IX) as a potential target for cancer therapy. Cancer Ther. 2004, 2, 245-262. Online: www.cancer-therapy.org.
133. Supuran, C.T.; Scozzafava, A. Carbonic anhydrase inhibitors and their therapeutic potential. Expert Opin. Ther. Pat. 2000, 10, 575-600.
134. Supuran, C. T.; Briganti, F.; Tilli, S.; Chegwidden, W. R.; Scozzafava, A. Carbonic anhydrase inhibitors: sulfonamides as antitumor agents? Bioorg. Med. Chem. Lett. 2001, 9, 703-714.
135. Vullo, D.; Franchi, M.; Gallori, E.; Pastorek, J.; Scozzafava, A.; Pastorekova, S.; Supuran, C. T. Carbonic anhydrase inhibitors. Inhibition of the tumor-associated isozyme IX with aromatic and heterocyclic sulfonamides. Bioorg. Med. Chem. Lett. 2003, 13, 1005-1009.
136. Jaiswal,M.;Khadikar, P.V.; Scozzafava, A.; Supuran, C. T. Carbonic anhydrase inhibitors:the first QSAR study on inhibition of tumor-associated isoenzyme IX with aromatic and heterocyclic sulfonamides. Bioorg. Med. Chem. Lett. 2004, 14, 3283-3290.
137. Ozensoy, O.; Pucetti, L.; Fasolis, G.; Arslan, O.; Scozzafava, A.; Supuran, C. T. Carbonic anhydrase inhibitors: inhibition of the tumor-associated isoenzymes IX and XII with a library of aromatic and heteroaromatic sulfonamides. Bioorg. Med. Chem. Lett. 2005, 15, 4862-4866.
138. Ilies, M. A.;Vullo, D.; Pastorek, J.; Scozzafava, A.; Ilies, M.; Caproiu, M. T.; Pastorekova, S.; Supuran, C. T. Carbonic anhydrase inhibitors. Inhibition of tumor-associated isozyme IX by halogenosulfanilamide and halogenophenylaminobenzolamide derivatives. J. Med. Chem. 2003, 46, 2187-2196.
139. Franchi, M.;Vullo, D.; Gallori, E.; Pastorek, J.; Russo, A.; Scozzafava, A.; Pastorekova, S.; Supuran, C. T. Carbonic anhydrase inhibitors. Inhibition of cytosolic isozymes I and II and transmembrane, cancer-associated isozyme IX with lipophilic sulfonamides. J. Enzyme Inhib. Med. Chem. 2003, 18, 333-338.
140. Winum, J.Y.; Pastorekova, S.; Jakubickova, L.; Montero, J. L.; Scozzafava, A.; Pastorek, J.; Vullo, D.; Innocenti, A.; Supuran, C. T. Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II and IX with bis-sulfamates. Bioorg. Med. Chem. Lett. 2005, 15, 573-578.
141. Garaj,V.; Pucetti, L.; Fasolis, G.;Winum, J.Y.; Montero, J. L.; Scozzafava, A.;Vullo, D.; Innocenti, A.; Supuran, C. T. Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with sulfonamides incorporating 1,2,4-triazine moieties. Bioorg. Med. Chem. Lett. 2004, 14, 5427-5433.
142. Garaj,V.; Pucetti, L.; Fasolis, G.;Winum, J.Y.; Montero, J. L.; Scozzafava, A.; Supuran, C. T. Carbonic anhydrase inhibitors: novel sulfonamides incorporating 1,3,5-triazine moieties as inhibitors of cytosolic and tumor-associated carbonic anhydrase isozymes I, II, and IX. Bioorg. Med. Chem. Lett. 2005, 15, 3102-3108.
143. Cecchi, A.; Winum, J. Y.; Innocenti, A.; Vullo, D.; Montero, J. L.; Scozzafava, A.; Supuran, C. T. Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/tumor associated carbonic anhydrase isozymes I, II, and IX with sulfonamides derived from 4-isothiocyanato-benzolamide. Bioorg. Med. Chem. Lett. 2004, 14, 5775-5780.
144. Abbate, F.; Casini, A.; Owa, T.; Scozzafava, A.; Supuran, C. T. Carbonic anhydrase inhibitors: E7070, a sulfonamide anticancer agent, potently inhibits cytosolic isozymes I and II, and transmembrane, tumor-associated isozyme IX. Bioorg. Med. Chem. Lett. 2004, 14, 225-229.
145. Pucetti, L.; Fasolis, G.; Cecchi, A.; Winum, J. Y.; Gamberi, A.; Montero, J. L.; Scozzafava, A.; Supuran, C. T. Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II and IX with sulfonamides incorporating thioureido-sulfanilyl scaffolds. Bioorg. Med. Chem. Lett. 2005, 15, 2359-2364.
146. Turkmen, H.; Dugrun, M.; Yilmaztekin, S.; Emul, M.; Innocenti, A.; Vullo, D.; Scozzafava, A.; Supuran, C. T. Carbonic anhydrase inhibitors: novel sulfanilamide/acetazolamide derivatives obtained by the tail approach and their interaction with the cytosolic isozymes I and II and the tumor-associated isozymes IX. Bioorg. Med. Chem. Lett. 2005, 17, 367-372.
147. Winum, J. Y.; Dogne, J. M.; Casini, A.; de Leval, X.; Montero, J. L.; Scozzafava, A.; Vullo, D.; Innocenti, A.; Supuran, C. T. Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II and IX with sulfonamides incorporating hydrazine moieties. J. Med. Chem. 2005, 48, 2121-2125.
148. Almajan, G. L.; Innocenti, A.; Pucetti, L.; Manole, G.; Berbuceanu, S.; Saramet, I.; Scozzafava, A.; Supuran, C. T. Carbonic anhydrase inhibitors: inhibition of the cytosolic and tumor-associated carbonic anhydrase isozymes I, II and IX with a series of 1,3,4-thiadiazole-and 1,2,4-triazole-thiols. Bioorg. Med. Chem. Lett. 2005, 15, 2347-2352.
149. Winum, J.Y.; Innocenti, A.; Nasr, J.; Montero, J. L.; Scozzafava, A.;Vullo, D.; Supuran, C. T. Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/tumorassociated carbonic anhydrase isozymes I, II and IX with N-hydroxysulfamides: a new zinc-binding function in the design of inhibitors. Bioorg. Med. Chem. Lett. 2005, 15, 2353-2358.
150. Pastorekova, S.; Vullo, D.; Casini, A.; Scozzafava, A.; Pastorek, J.; Nishimori, I.; Supuran, C. T. Carbonic anhydrase inhibitors: synthesis and inhibition of the tumorassociated isozymes IX and XII with polyfluorinated aromatic/heterocyclic sulfonamides. J. Enzyme Inhib. Med. Chem. 2005, 20, 211-217.
151. Innocenti, A.; Villar, R.; Martinez-Merino, V.; Gil, M. J.; Scozzafava, A.; Vullo, D.; Supuran, C. T. Carbonic anhydrase inhibitors: inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II and IX with benzo[b]thiophene 1,1 dioxide sulfonamides. Bioorg. Med. Chem. Lett. 2005, 15, 4872-4876.
152. Cecchi, A.; Taylor, S. D.; Liu, Y.; Hill, B.; Vullo, D.; Scozzafava, A.; Supuran, C. T. Carbonic anhydrase inhibitors: inhibition of the human isozymes I, II, VA and IX with a library of substituted difluoromethanesulfinamides. Bioorg. Med. Chem. Lett. 2005, 15, 5192-5196.
153. Thiry, A.; Ledecq, M.; Cecchi, A.; Dogne, J. M.;Wouters, J.; Supuran, C. T.; Masereel, B. Indanesulfonamides as carbonic anhydrase inhibitors. Toward structure-based design of selective inhibitors of the tumor-associated isozyme CA IX. J. Med. Chem. 2006, 49, 2743-2749.
154. Rami, M.;Winum, J. Y.; Innocenti, A.; Montero, J. L.; Scozzafava, A.; Supuran, C. T. Carbonic anhydrase inhibitors: copper(II) complexes of polyamino-polycarboxylamido aromatic/heterocyclic sulfonamides are very potent inhibitors of the tumor-associated isoforms IX and XII. Bioorg. Med. Chem. Lett. 2008, 18, 836-841.
155. Weber, A.; Casini, A.; Heine, A.; Kuhn, D.; Supuran, C. T.; Scozzafava, A.; Klebe, G. Unexpected nanomolar inhibition of carbonic anhydrase by COX-2-selective celecoxib:newpharmacological opportunities due to related binding site recognition. J. Med. Chem. 2004, 47, 550-557.
156. Dogné, J. M.; Thiry, A.; Pratico, D.; Masereel, B.; Supuran, C. T. Dual carbonic anhydrase-cyclooxygenase-2 inhibitors. Curr. Top. Med. Chem. 2007, 7, 885-891.
157. Temperini, C.; Innocenti, A.; Mastrolorenzo, A.; Scozzafava, A.; Supuran, C. T. Carbonic anhydrase inhibitors. Interaction of the antiepileptic drug sulthiame with twelve mammalian isoforms: kinetic and X-ray crystallographic studies. Bioorg. Med. Chem. Lett. 2007, 17, 4866-4872.
158. Scozzafava, A.; Mastrolorenzo, A.; Supuran, C.T. Modulation of carbonic anhydrase activity and its applications in therapy. Expert Opin. Ther. Pat. 2004, 14, 667-702.
159. Winum, J. Y.; Scozzafava, A.; Montero, J. L.; Supuran, C. T. Design of zinc binding functions for carbonic anhydrase inhibitors. Curr. Pharm. Des. 2008, 14, 615-621.
160. Casey, J. R.; Morgan, P. E.; Vullo, D.; Scozzafava, A.; Mastrolorenzo, A.; Supuran, C. T. Carbonic anhydrase inhibitors. Design of selective, membrane-impermeant inhibitors targeting the human tumor-associated isozyme IX. J. Med. Chem. 2004, 47, 2337-2347.
161. Pastorekova, S.; Casini, A.; Scozzafava, A.; Vullo, D.; Pastorek, J.; Supuran, C. T. Carbonic anhydrase inhibitors: the first selective, membrane-impermeant inhibitors targeting the tumor-associated isozyme IX. Bioorg. Med. Chem. Lett. 2004, 14, 869-873.
162. Smaine, F. Z.; Winum, J. Y.; Montero, J. L.; Regainia, Z.; Vullo, D.; Scozzafava, A.; Supuran, C. T. Carbonic anhydrase inhibitors: selective inhibition of the extracellular, tumor-associated isoforms IX and XII over isozymes I and II with glycosyl-thioureidosulfonamides. Bioorg. Med. Chem. Lett. 2007, 17, 5096-5100.
163. Saczewski, F.; Sławiński, J.; Kornicka, A.; Brzozowski, Z.; Pomarnacka, E.; Innocenti, A.; Scozzafava, A.; Supuran, C. T. Carbonic anhydrase inhibitors. Inhibition of the cytosolic human isozymes I and II, and the transmembrane, tumor-associated isozymes IX and XII with substituted aromatic sulfonamides activatable in hypoxic tumors. Bioorg. Med. Chem. Lett. 2006, 16, 4846-4851.
164. Cecchi, A.; Hulikova, A.; Pastorek, J.; Pastorekova, S.; Scozzafava, A.;Winum, J. Y.; Montero, J. L.; Supuran, C. T. Carbonic anhydrase inhibitors. Design of fluorescent sulfonamides as probes of tumor-associated carbonic anhydrase IX that inhibit isozyme IX-mediated acidification of hypoxic tumors. J. Med. Chem. 2005, 48, 4834-4841.
165. Dubois, L.; Douma, K.; Supuran, C. T-; Chiu R. K.; van Zandvoort, M. A.; Pastorekovä, S.; Scozzafava, A.;Wouters, B. G.; Lambin, P. Imaging the hypoxia surrogate marker CA IX requires expression and catalytic activity for binding fluorescent sulfonamide inhibitors. Radiother. Oncol. 2007, 83, 367-373.
166. Alterio, V.; Vitale, R. M.; Monti, S. M.; Pedone, C.; Scozzafava, A.; Cecchi, A.; De Simone, G.; Supuran, C. T. Carbonic anhydrase inhibitors: X-ray and molecular modeling study for the interaction of a fluorescent antitumor sulfonamide with isozyme II and IX. J. Am. Chem. Soc. 2006, 128, 8329-8335.
167. Cecchi, A.; Ciani, L.;Winum, J.Y.; Montero, J. L.; Scozzafava, A.; Ristori, S.; Supuran, C. T. Carbonic anhydrase inhibitors: design of spin-labeled sulfonamides incorporating TEMPO moieties as probes for cytosolic or transmembrane isozymes. Bioorg. Med. Chem. Lett. 2008, 18, 3475-3480.
168. Vukovic, V.; Tannock, I. F. Influence of the pH on cytotoxicity of paclitaxel, mitoxanthrone and topotecan. Br. J. Cancer 1997, 75, 1167-1172.
169. Kozin, S. V.; Shkarin, P.; Gerweck, L. E. The cell transmembrane pH gradient in tumors enhances cytotoxicity of specific weak acid chemotherapeutics. Cancer Res. 2001, 61, 4740-4743.
170. Teicher, B. A.; Liu, S. D.; Liu, J. T.; Holden, S. A.; Herman, T. S. A carbonic anhydrase inhibitor is potential modulator of cancer therapies. Anticancer Res. 1993, 13, 1549-1556.
171. Winum, J. Y.; Cecchi, A.; Montero, J. L.; Innocenti, A.; Scozzafava, A.; Supuran, C. T. Carbonic anhydrase inhibitors. Synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II and IX with boron-containing sulfonamides, sulfamides and sulfamates: towards agents for boron neutron capture therapy of hypoxic tumors. Bioorg. Med. Chem. Lett. 2005, 15, 3302-3306.
172. Pastorekova, S.; Ratcliffe, P. J.; Pastorek, J. Molecular mechanisms of carbonic anhydrase IX-mediated pH regulation under hypoxia. BJU Int. 2008, 101 (Suppl. 4), 8-15.
173. Thiry, A.; Supuran, C. T.; Masereel, B.; Dogné, J. M. Recent developments of carbonic anhydrase inhibitors as potential anticancer drugs. J. Med. Chem. 2008, 51, 3051-3056.
174. Potter, C. P.; Harris, A. L. Diagnostic, prognostic and therapeutic implications of carbonic anhydrases in cancer. Br. J. Cancer 2003, 89, 2-7.